The document discusses the expanding value of oncology treatments over time. It analyzes 10 cancer drugs approved by the EMA between 2003-2005 to see how their value expanded beyond initial indications. Seven of the 10 drugs gained additional approved uses over time. Health technology assessment bodies need to recognize how product lifecycles affect value, especially for cancer drugs, as innovations may be demonstrated through expanding uses over time. This has implications for designing health technology assessment systems.